Does the media favor PYXS or TLRY?

In the previous week, Tilray Brands had 20 more articles in the media than Pyxis Oncology. MarketBeat recorded 23 mentions for Tilray Brands and 3 mentions for Pyxis Oncology. Tilray Brands' average media sentiment score of 0.68 beat Pyxis Oncology's score of 0.62 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tilray Brands 8 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMMX or PYXS more profitable?

Immix Biopharma's return on equity of -73.24% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Immix Biopharma N/A -73.24% -59.20% Pyxis Oncology N/A -135.60% -85.00%

Does the media prefer IMMX or PYXS?

In the previous week, Pyxis Oncology had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.96 beat Pyxis Oncology's score of 0.62 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, EIKN or PYXS?

Eikon Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A N/A N/A N/A Pyxis Oncology $13.86M 13.07 -$79.62M -$1.31 N/A

Is EIKN or PYXS more profitable?

Eikon Therapeutics' return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A Pyxis Oncology N/A -135.60% -85.00%

Does the media prefer EIKN or PYXS?

In the previous week, Eikon Therapeutics had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Eikon Therapeutics and 3 mentions for Pyxis Oncology. Eikon Therapeutics' average media sentiment score of 0.89 beat Pyxis Oncology's score of 0.62 indicating that Eikon Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MNPR or PYXS more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Pyxis Oncology N/A -135.60% -85.00%

Does the media prefer MNPR or PYXS?

In the previous week, Monopar Therapeutics had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 5 mentions for Monopar Therapeutics and 3 mentions for Pyxis Oncology. Monopar Therapeutics' average media sentiment score of 0.62 beat Pyxis Oncology's score of 0.62 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pyxis Oncology (PYXS) Competitors

$2.86 +0.09 (+3.25%)

Closing price 04:00 PM Eastern

Extended Trading

$2.90 +0.04 (+1.54%)

As of 07:58 PM Eastern

Compare

PYXS vs. TLRY, IMMX, CTMX, EIKN, and MNPR

Should you buy Pyxis Oncology stock or one of its competitors? MarketBeat compares Pyxis Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pyxis Oncology include Tilray Brands (TLRY), Immix Biopharma (IMMX), CytomX Therapeutics (CTMX), Eikon Therapeutics (EIKN), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry.

How does Pyxis Oncology compare to Tilray Brands?

Pyxis Oncology (NASDAQ:PYXS) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

Pyxis Oncology has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Tilray Brands	-156.51%	-3.31%	-2.42%

In the previous week, Tilray Brands had 20 more articles in the media than Pyxis Oncology. MarketBeat recorded 23 mentions for Tilray Brands and 3 mentions for Pyxis Oncology. Tilray Brands' average media sentiment score of 0.68 beat Pyxis Oncology's score of 0.62 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tilray Brands	8 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pyxis Oncology has higher earnings, but lower revenue than Tilray Brands. Pyxis Oncology is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A
Tilray Brands	$210.48M	2.55	-$2.19B	-$13.65	N/A

Pyxis Oncology currently has a consensus price target of $6.83, suggesting a potential upside of 138.93%. Tilray Brands has a consensus price target of $11.50, suggesting a potential upside of 149.46%. Given Tilray Brands' higher probable upside, analysts plainly believe Tilray Brands is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Pyxis Oncology and Tilray Brands tied by winning 8 of the 16 factors compared between the two stocks.

How does Pyxis Oncology compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Immix Biopharma has higher earnings, but lower revenue than Pyxis Oncology. Immix Biopharma is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.92	N/A
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immix Biopharma's return on equity of -73.24% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-73.24%	-59.20%
Pyxis Oncology	N/A	-135.60%	-85.00%

Immix Biopharma presently has a consensus price target of $20.67, suggesting a potential upside of 97.01%. Pyxis Oncology has a consensus price target of $6.83, suggesting a potential upside of 138.93%. Given Pyxis Oncology's higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Pyxis Oncology had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.96 beat Pyxis Oncology's score of 0.62 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immix Biopharma has a beta of 0.11, suggesting that its stock price is 89% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

Summary

Immix Biopharma beats Pyxis Oncology on 8 of the 14 factors compared between the two stocks.

How does Pyxis Oncology compare to CytomX Therapeutics?

Pyxis Oncology (NASDAQ:PYXS) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Pyxis Oncology presently has a consensus target price of $6.83, indicating a potential upside of 138.93%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 223.53%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pyxis Oncology has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, Pyxis Oncology had 2 more articles in the media than CytomX Therapeutics. MarketBeat recorded 3 mentions for Pyxis Oncology and 1 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 1.89 beat Pyxis Oncology's score of 0.62 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pyxis Oncology	Positive
CytomX Therapeutics	Very Positive

Pyxis Oncology has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market.

CytomX Therapeutics has higher revenue and earnings than Pyxis Oncology. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A
CytomX Therapeutics	$35.54M	17.91	-$17.37M	-$0.41	N/A

Summary

CytomX Therapeutics beats Pyxis Oncology on 13 of the 17 factors compared between the two stocks.

How does Pyxis Oncology compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Eikon Therapeutics has higher earnings, but lower revenue than Pyxis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	N/A	N/A
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A

Eikon Therapeutics' return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
Pyxis Oncology	N/A	-135.60%	-85.00%

In the previous week, Eikon Therapeutics had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Eikon Therapeutics and 3 mentions for Pyxis Oncology. Eikon Therapeutics' average media sentiment score of 0.89 beat Pyxis Oncology's score of 0.62 indicating that Eikon Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eikon Therapeutics presently has a consensus price target of $25.20, suggesting a potential upside of 97.80%. Pyxis Oncology has a consensus price target of $6.83, suggesting a potential upside of 138.93%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

39.1% of Pyxis Oncology shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Pyxis Oncology beats Eikon Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Pyxis Oncology compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Monopar Therapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

In the previous week, Monopar Therapeutics had 2 more articles in the media than Pyxis Oncology. MarketBeat recorded 5 mentions for Monopar Therapeutics and 3 mentions for Pyxis Oncology. Monopar Therapeutics' average media sentiment score of 0.62 beat Pyxis Oncology's score of 0.62 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics' return on equity of -12.84% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Pyxis Oncology	N/A	-135.60%	-85.00%

Monopar Therapeutics currently has a consensus target price of $107.67, suggesting a potential upside of 13.86%. Pyxis Oncology has a consensus target price of $6.83, suggesting a potential upside of 138.93%. Given Pyxis Oncology's higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than Pyxis Oncology. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A

Summary

Monopar Therapeutics beats Pyxis Oncology on 10 of the 15 factors compared between the two stocks.

Get Pyxis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYXS vs. The Competition

Export

Metric	Pyxis Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$181.18M	$3.06B	$6.84B	$12.43B
Dividend Yield	N/A	1.87%	2.67%	6.11%
P/E Ratio	-2.18	19.67	25.83	24.36
Price / Sales	13.07	358.40	511.51	84.16
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	3.33	4.25	10.98	6.49
Net Income	-$79.62M	$64.45M	$3.57B	$336.61M
7 Day Performance	34.27%	4.17%	3.06%	0.90%
1 Month Performance	58.89%	1.44%	0.72%	-0.36%
1 Year Performance	160.00%	34.07%	36.82%	31.26%

Pyxis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYXS Pyxis Oncology	2.6786 of 5 stars	$2.86 +3.2%	$6.83 +138.9%	+151.8%	$181.18M	$13.86M	N/A	60
TLRY Tilray Brands	2.8571 of 5 stars	$4.64 +1.0%	$11.50 +148.1%	+15.8%	$541.37M	$210.48M	N/A	2,842
IMMX Immix Biopharma	3.5834 of 5 stars	$9.82 +4.4%	$20.67 +110.5%	+359.9%	$537.03M	N/A	N/A	9
CTMX CytomX Therapeutics	2.8365 of 5 stars	$3.14 +3.1%	$12.10 +286.0%	+50.4%	$535.24M	$35.54M	N/A	170	Gap Up
EIKN Eikon Therapeutics	N/A	$9.72 +1.0%	$25.20 +159.4%	N/A	$525.96M	N/A	N/A	384

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYXS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Competitors

PYXS vs. TLRY, IMMX, CTMX, EIKN, and MNPR

How does Pyxis Oncology compare to Tilray Brands?

Summary

How does Pyxis Oncology compare to Immix Biopharma?

Summary

How does Pyxis Oncology compare to CytomX Therapeutics?

Summary

How does Pyxis Oncology compare to Eikon Therapeutics?

Summary

How does Pyxis Oncology compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pyxis Oncology (PYXS) Competitors

PYXS vs. TLRY, IMMX, CTMX, EIKN, and MNPR

How does Pyxis Oncology compare to Tilray Brands?

Which has more risk and volatility, PYXS or TLRY?

Is PYXS or TLRY more profitable?

Does the media favor PYXS or TLRY?

Do institutionals and insiders hold more shares of PYXS or TLRY?

Which has preferable earnings and valuation, PYXS or TLRY?

Do analysts prefer PYXS or TLRY?

Summary

How does Pyxis Oncology compare to Immix Biopharma?

Which has higher valuation and earnings, IMMX or PYXS?

Do institutionals & insiders have more ownership in IMMX or PYXS?

Is IMMX or PYXS more profitable?

Do analysts prefer IMMX or PYXS?

Does the media prefer IMMX or PYXS?

Which has more risk & volatility, IMMX or PYXS?

Summary

How does Pyxis Oncology compare to CytomX Therapeutics?

Do analysts prefer PYXS or CTMX?

Do institutionals and insiders believe in PYXS or CTMX?

Is PYXS or CTMX more profitable?

Does the media favor PYXS or CTMX?

Which has more risk and volatility, PYXS or CTMX?

Which has higher valuation and earnings, PYXS or CTMX?

Summary

How does Pyxis Oncology compare to Eikon Therapeutics?

Which has stronger valuation & earnings, EIKN or PYXS?

Is EIKN or PYXS more profitable?

Does the media prefer EIKN or PYXS?

Do analysts recommend EIKN or PYXS?

Do institutionals & insiders hold more shares of EIKN or PYXS?

Summary

How does Pyxis Oncology compare to Monopar Therapeutics?

Which has more volatility and risk, MNPR or PYXS?

Does the media prefer MNPR or PYXS?

Is MNPR or PYXS more profitable?

Do analysts recommend MNPR or PYXS?

Do insiders & institutionals hold more shares of MNPR or PYXS?

Which has better earnings and valuation, MNPR or PYXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools